Fasenra Generic Name & Formulations
Benralizumab 30mg/mL; soln for SC inj; preservative-free.
Single-dose prefilled syringe—1; Single-dose autoinjector (pen)—1
As add-on maintenance treatment of severe asthma in patients ≥12yrs old, and with an eosinophilic phenotype.
Limitations of Use
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.
Fasenra Dosage and Administration
Give by SC inj into upper arm, thigh, or abdomen. 30mg once every 4 weeks for the first 3 doses, then once every 8 weeks thereafter.
<12yrs: not established.
Fasenra Boxed Warnings
Not for treating acute asthma symptoms or exacerbations. Discontinue if hypersensitivity reactions occur. Treat pre-existing helminth infections before initiating therapy; discontinue Fasenra if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt discontinuation of systemic or inhaled corticosteroids; reduce dose gradually upon Fasenra initiation, if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.
Fasenra Adverse Reactions
Headache, pharyngitis, pyrexia, hypersensitivity reactions.
Fasenra Clinical Trials
Fasenra Patient Counseling